Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in Mol Cancer Ther Retrieve available abstracts of 36 articles: HTML format Text format

Single Articles

June 2018
1. SHIN DH, Jo JY, Han JY
   Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer.
   Mol Cancer Ther. 2018 Jun 29. pii: 1535-7163.MCT-17-1178.
   PubMed     Text format     Abstract available
   
   
   
2. NJATCHA C, Farooqui M, Kornberg A, Johnson DE, et al
   STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
   Mol Cancer Ther. 2018 Jun 11. pii: 1535-7163.MCT-17-1194.
   PubMed     Text format     Abstract available
   
   
   April 2018
3. BOCKORNY B, Rusan M, Chen W, Liao RG, et al
   RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
   Mol Cancer Ther. 2018 Apr 13. pii: 1535-7163.MCT-17-0464.
   PubMed     Text format     Abstract available
   
   
   February 2018
4. HIRANO T, Yasuda H, Hamamoto J, Nukaga S, et al
   Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.
   Mol Cancer Ther. 2018 Feb 21. pii: 1535-7163.MCT-17-1033.
   PubMed     Text format     Abstract available
   
   
   October 2017
5. YAMADA T, Amann JM, Tanimoto A, Taniguchi H, et al
   Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations.
   Mol Cancer Ther. 2017 Oct 27. pii: molcanther.0146.2017.
   PubMed     Text format     Abstract available
   
   
   August 2017
6. AKENO N, Reece AL, Callahan M, Miller AL, et al
   Trp53 Mutants Drive Neuroendocrine Lung Cancer through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
   Mol Cancer Ther. 2017 Aug 28. pii: molcanther.0353.2017.
   PubMed     Text format     Abstract available
   
   
   
7. WATANABE S, Yoshida T, Kawakami H, Takegawa N, et al
   T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer.
   Mol Cancer Ther. 2017 Aug 24. pii: molcanther.0351.2017.
   PubMed     Text format     Abstract available
   
   
   July 2017
8. SHIEN K, Papadimitrakopoulou VA, Ruder D, Behrens C, et al
   JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer.
   Mol Cancer Ther. 2017 Jul 20. pii: molcanther.0148.2016.
   PubMed     Text format     Abstract available
   
   
   May 2017
9. GAUTAM J, Ku JM, Regmi SC, Jeong H, et al
   Dual inhibition of NOX2 and receptor tyrosine kinase by BJ-1301 enhances anticancer therapy efficacy via suppression of autocrine stimulatory factors in lung cancer.
   Mol Cancer Ther. 2017 May 23. pii: molcanther.0915.2016.
   PubMed     Text format     Abstract available
   
   
   
10. RAIMBOURG J, Joalland MP, Cabart M, de Plater L, et al
    Sensitization of EGFR wild-type non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitor erlotinib.
    Mol Cancer Ther. 2017 May 18. pii: molcanther.0075.2017.
    PubMed     Text format     Abstract available
    
    
    
11. ROSS KC, Andrews AJ, Marion CD, Yen TJ, et al
    Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells.
    Mol Cancer Ther. 2017 May 12. pii: molcanther.0798.2016.
    PubMed     Text format     Abstract available
    
    
    
12. LAM LT, Lin X, Faivre EJ, Yang Z, et al
    Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors.
    Mol Cancer Ther. 2017 May 3. pii: molcanther.0459.2016.
    PubMed     Text format     Abstract available
    
    
    
13. CHATTERJEE S, Huang EH, Christie I, Kurland BF, et al
    Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network.
    Mol Cancer Ther. 2017;16:793-804.
    PubMed     Text format     Abstract available
    
    
    April 2017
14. MANUEL-MANRESA P, Korrodi-Gregorio L, Hernando E, Villanueva A, et al
    Novel indole-based tambjamine-analogues induce apoptotic lung cancer cell death through p38 mitogen-activated protein kinase activation.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0752.2016.
    PubMed     Text format     Abstract available
    
    
    
15. GIMENEZ-XAVIER P, Pros E, Bonastre E, Moran S, et al
    Genomic and molecular screenings identify different mechanisms for acquired resistance to MET inhibitors in lung cancer cells.
    Mol Cancer Ther. 2017 Apr 10. pii: molcanther.0104.2017.
    PubMed     Text format     Abstract available
    
    
    
16. SALGIA R
    MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale.
    Mol Cancer Ther. 2017;16:555-565.
    PubMed     Text format     Abstract available
    
    
    March 2017
17. WOO JK, Jang JE, Kang JH, Seong JK, et al
    Lectin, galactoside-binding soluble 3 binding protein promotes 17-N-Allylamino-17-demethoxygeldanamycin resistance through PI3K/Akt pathway in lung cancer cell line.
    Mol Cancer Ther. 2017 Mar 23. pii: molcanther.0574.2016.
    PubMed     Text format     Abstract available
    
    
    
18. WILLUDA J, Linden L, Lerchen HG, Kopitz C, et al
    Preclinical Anti-Tumor Efficacy of BAY 1129980 - a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-small Cell Lung Cancer.
    Mol Cancer Ther. 2017 Mar 14. pii: molcanther.0474.2016.
    PubMed     Text format     Abstract available
    
    
    February 2017
19. HUSAIN H, Scur M, Murtuza A, Bui N, et al
    Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.
    Mol Cancer Ther. 2017;16:265-272.
    PubMed     Text format     Abstract available
    
    
    January 2017
20. NANJO S, Arai S, Wang W, Takeuchi S, et al
    MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer.
    Mol Cancer Ther. 2017 Jan 30. pii: molcanther.0522.2016.
    PubMed     Text format     Abstract available
    
    
    
21. HAAK AJ, Appleton KM, Lisabeth EM, Misek SA, et al
    Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.
    Mol Cancer Ther. 2017;16:193-204.
    PubMed     Text format     Abstract available
    
    
    December 2016
22. KOBAYASHI Y, Azuma K, Nagai H, Kim YH, et al
    Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer.
    Mol Cancer Ther. 2016 Dec 2. pii: molcanther.0407.2016.
    PubMed     Text format     Abstract available
    
    
    November 2016
23. NAKAMURA Y, Weaver Ohler Z, Householder D, Nagaya T, et al
    Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer.
    Mol Cancer Ther. 2016 Nov 15. pii: molcanther.0663.2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
24. XU X, Mao L, Xu W, Tang W, et al
    AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients.
    Mol Cancer Ther. 2016 Aug 29. pii: molcanther.0281.2016.
    PubMed     Text format     Abstract available
    
    
    
25. DANILOV AV, Hu S, Orr B, Godek K, et al
    Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2.
    Mol Cancer Ther. 2016 Aug 22. pii: molcanther.0127.2016.
    PubMed     Text format     Abstract available
    
    
    July 2016
26. MCLAUGHLIN KA, Nemeth Z, Bradley CA, Humphreys L, et al
    FLIP: a targetable mediator of resistance to radiation in non-small cell lung cancer.
    Mol Cancer Ther. 2016 Jul 29. pii: molcanther.0211.2016.
    PubMed     Text format     Abstract available
    
    
    May 2016
27. JHURANEY A, Woods NT, Wright G, Rix L, et al
    PAXIP1 potentiates the combination of WEE1 inhibitor AZD1775 and platinum agents in lung cancer.
    Mol Cancer Ther. 2016 May 11. pii: molcanther.0182.2015.
    PubMed     Text format     Abstract available
    
    
    February 2016
28. WAN L, Sun M, Liu GJ, Wei CC, et al
    Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression.
    Mol Cancer Ther. 2016 Feb 23. pii: molcanther.0707.2015.
    PubMed     Text format     Abstract available
    
    
    
29. JANG JY, Kim YG, Nam SJ, Keam B, et al
    Targeting adenine nucleotide translocase-2 (ANT2) to overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer.
    Mol Cancer Ther. 2016 Feb 16. pii: molcanther.0089.2015.
    PubMed     Text format     Abstract available
    
    
    
30. ONION D, Argent RH, Reece-Smith AM, Craze ML, et al
    3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal cells but Sensitivity to Histone Deacetylase Inhibitors.
    Mol Cancer Ther. 2016 Feb 12. pii: molcanther.0598.2015.
    PubMed     Text format     Abstract available
    
    
    
31. FENG J, Zhang S, Wu K, Wang B, et al
    Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-small-cell Lung Cancer.
    Mol Cancer Ther. 2016 Feb 2. pii: molcanther.0445.2015.
    PubMed     Text format     Abstract available
    
    
    January 2016
32. LI J, Fang B, Kinose F, Bai Y, et al
    Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling.
    Mol Cancer Ther. 2016 Jan 15. pii: molcanther.0444.2015.
    PubMed     Text format     Abstract available
    
    
    December 2015
33. TANI T, Yasuda H, Hamamoto J, Kuroda A, et al
    Activation of EGFR bypass signaling by TGFalpha overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells.
    Mol Cancer Ther. 2015 Dec 18. pii: molcanther.0084.2015.
    PubMed     Text format     Abstract available
    
    
    
34. ZUBOVYCH IO, Sethi A, Kulkarni A, Tagal V, et al
    A Novel Inhibitor Of Topoisomerase I is Selectively Toxic For A Subset of Non-Small Cell Lung Cancer Cell Lines.
    Mol Cancer Ther. 2015 Dec 14. pii: molcanther.0458.2015.
    PubMed     Text format     Abstract available
    
    
    
35. ALHAKAMY NA, Ishiguro S, Uppalapati D, Berkland CJ, et al
    AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray.
    Mol Cancer Ther. 2015 Dec 4. pii: molcanther.0448.2015.
    PubMed     Text format     Abstract available
    
    
    March 2015
36. NAKANISHI Y, Akiyama N, Tsukaguchi T, Fujii T, et al
    Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
    Mol Cancer Ther. 2015;14:704-12.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: